Cytodyn

About Cytodyn

CytoDyn Inc. is a clinical-stage biotechnology company centered on the development of leronlimab, a humanized monoclonal antibody. Incorporated in 2002 as RexRay Corporation and based in Vancouver, Washington, the company's primary focus is on leveraging leronlimab as a CCR5 antagonist for multiple therapeutic applications. The company operates as a pre-revenue entity, financing its operations through the sale of stock, as it currently has no marketable products and generates no revenue from sales.

The company's journey has been marked by significant leadership and regulatory challenges. In January 2022, the board terminated Nader Pourhassan, who had been CEO since 2012. This followed a period of intense scrutiny, including a rare public rebuke from the FDA in May 2021 for misrepresenting clinical trial data for leronlimab's use in COVID-19. Subsequently, the company faced investigations from the SEC and the Department of Justice regarding these public statements. These events culminated in the conviction of former CEO Nader Pourhassan and Kazem Kazempour, the head of a contract research organization (CRO) hired by CytoDyn, on multiple counts of fraud and insider trading for misleading investors about the drug's regulatory progress and clinical viability between 2018 and 2021. As of January 2024, Jacob Lalezari, M.D., was appointed CEO to guide the company forward.

Leronlimab is an investigational antibody designed to bind to the C-C chemokine receptor type 5 (CCR5), a protein found on the surface of various cells, including immune cells. This receptor is crucial for certain strains of HIV to infect healthy T-cells and is also implicated in inflammatory processes and tumor metastasis. Leronlimab acts as a competitive inhibitor, a mechanism that differentiates it from other CCR5 antagonists. The product is administered via a weekly subcutaneous injection or intravenously. The company is exploring its potential to treat HIV, oncology indications like metastatic triple-negative breast cancer (mTNBC) and colorectal cancer, and inflammatory conditions such as metabolic dysfunction-associated steatohepatitis (MASH). Recent research suggests leronlimab may convert immunologically "cold" tumors into "hot" ones by increasing PD-L1 expression, potentially making them more responsive to checkpoint inhibitor therapies.

CytoDyn's clinical development has experienced notable setbacks and recent progress. In March 2022, the FDA placed a full clinical hold on its COVID-19 program and a partial hold on its HIV program. However, in February 2024, the FDA lifted the clinical hold, allowing the company to proceed with a new HIV clinical trial focused on chronic inflammation. More recently, in November 2024, the company received FDA clearance to begin a Phase II trial for leronlimab in patients with microsatellite stable colorectal cancer.